false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Advance ...
Introduction to Targeting the Kidneys with Nanopar ...
Introduction to Targeting the Kidneys with Nanoparticles and AAVs
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Matt Wilson surveys gene-delivery technologies being developed for kidney disease, focusing on adeno-associated viral (AAV) vectors and nanoparticles. Despite growing global approvals for cell and gene therapies—including CRISPR and dual-AAV treatments—none currently target the kidney. Progress has been limited by the organ’s complex structure, diverse nephron segments and cell types, and the glomerulus’s size- and charge-based filtration barriers. Speakers will present approaches targeting specific kidney cells and diseases, including nanoparticle delivery of RNA and drugs, engineered AAVs for tubular and glomerular cells, and therapies for polycystic kidney disease, Alport syndrome, and diabetic nephropathy. Early findings in organoids and large-animal models may support clinical translation. Key priorities include improving cell-specific delivery, studying diseased kidneys and immune responses, refining vectors, and expanding large-animal research. Remaining challenges include toxicity at high doses, limited repeat dosing, uncertain long-term effects, small patient populations, funding and industry support, and the high cost of treatment.
Asset Caption
Matthew H. Wilson, MD, PhD
Meta Tag
Speaker
Matthew Wilson
Keywords
kidney disease gene delivery
AAV vectors
nanoparticle delivery
glomerular barriers
renal therapeutics
Matthew Wilson
×
Please select your language
1
English